Your browser doesn't support javascript.
loading
Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: a 52-week phase III randomised study.
Matsuno, Hiroaki; Kang, Young Mo; Okada, Masato; Lee, Sang-Il; Park, Sung-Hwan; Sheen, Dong Hyuk; Sato, Masaki; Hagino, Atsushi; Lee, Jiyoon; Shin, Seonghye; Song, Yeong Wook.
Affiliation
  • Matsuno H; Matsuno Clinic for Rheumatic Disease, Toyama, and Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
  • Kang YM; Division of Rheumatology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, South Korea.
  • Okada M; Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
  • Lee SI; Division of Rheumatology, Gyeongsang National University Hospital, Jinju, South Korea.
  • Park SH; Division of Rheumatology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea.
  • Sheen DH; Division of Rheumatology, Eulji University School of Medicine, Daejeon, South Korea.
  • Sato M; Mochida Pharmaceutical Co. Ltd., Tokyo, Japan.
  • Hagino A; Mochida Pharmaceutical Co. Ltd., Tokyo, Japan.
  • Lee J; LG Chem Ltd., Seoul, South Korea.
  • Shin S; LG Chem Ltd., Seoul, South Korea.
  • Song YW; Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. ysong@snu.ac.kr.
Clin Exp Rheumatol ; 40(5): 1025-1033, 2022 May.
Article in En | MEDLINE | ID: mdl-34251303

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Antirheumatic Agents / Biosimilar Pharmaceuticals Type of study: Clinical_trials / Diagnostic_studies Limits: Humans Language: En Journal: Clin Exp Rheumatol Year: 2022 Document type: Article Affiliation country: Japan Country of publication: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Antirheumatic Agents / Biosimilar Pharmaceuticals Type of study: Clinical_trials / Diagnostic_studies Limits: Humans Language: En Journal: Clin Exp Rheumatol Year: 2022 Document type: Article Affiliation country: Japan Country of publication: Italy